A Phase 1/2a Open-Label Study to Determine the Safety and Tolerability of ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas Expressing Wild-Type p53 Protein

Trial Profile

A Phase 1/2a Open-Label Study to Determine the Safety and Tolerability of ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas Expressing Wild-Type p53 Protein

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs ALRN 6924 (Primary)
  • Indications Carcinoma; Haematological malignancies; Peripheral T-cell lymphoma; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms All-comers
  • Sponsors Aileron Therapeutics
  • Most Recent Events

    • 10 Aug 2017 According to an Aileron Therapeutics media release, interim results from phase 2a part of this trial is expected in the first half of 2018.
    • 03 Jun 2017 Results (n = 41) published in an Aileron Therapeutics media release
    • 02 Jun 2017 Results (n=69) from phase I part of the study assessing the safety, tolerability, pharmacokinetic, pharmacodynamic and anti-tumour effects of ALRN-6924 in patients with advanced solid tumors or lymphomas, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top